Desperate patients get early access to platelet-boosting drug
NCT ID NCT04837703
First seen Dec 16, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This program provides early access to ETB115 (eltrombopag) for people with thrombocytopenia (low blood platelets) who have no other treatment options and cannot join a clinical trial. It is for patients with serious or life-threatening conditions where the potential benefit outweighs the risks. The goal is to manage the disease by raising platelet counts, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.